In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis Faith Borgan, Heikki Laurikainen, Mattia Veronese, Tiago Reis Marques, Merja Haaparanta-Solin, Olof Solin, Tarik Dahoun, Maria Rogdaki, Raimo KR Salokangas, Max Karukivi, Marta Di Forti, Federico Turkheimer, Jarmo Hietala, Oliver Howes for the METSY Group JAMA Psychiatry, 2019. doi : 10.1001/jamapsychiatry.2019.1427 IMPORTANCE Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether they are linked to cognitive function or symptom severity remain unknown. OBJECTIVE To investigate CB1R availability in first-episode psychosis (FEP) without the [...]
Lire la suiteCannabidiol as a potential treatment for psychosis Cathy Davies and Sagnik Bhattacharyya Therapeutic Advances in Psychopharmacology, 2019, Vol. 9, 1–16 https://doi.org/10.1177%2F2045125319881916 Abstract : Psychotic disorders such as schizophrenia are heterogeneous and often debilitating conditions that contribute substantially to the global burden of disease. The introduction of dopamine D2 receptor antagonists in the 1950s revolutionised the treatment of psychotic disorders and they remain the mainstay of our treatment arsenal for psychosis. However, traditional antipsychotics are associated with a number of side effects and a significant proportion of patients do not achieve an adequate remission of symptoms. There is therefore a need for novel interventions, particularly those with a non-D2 antagonist mechanism of [...]
Lire la suiteThe effect of cannabis laws on opioid use. J.L. Flexon, L. Stolzenberg, S.J. d'Alessio International Journal of Drug Policy, 2019, 74, 152-159. doi : 10.1016/j.drugpo.2019.09.013. Abstract BACKGROUND : Many Americans rely on opioids at varying dosages to help ameliorate their suffering. However, empirical evidence is mounting that opioids are ineffective at controlling non-cancer related chronic pain, and many argue the strategies meant to relieve patient suffering are contributing to the growing opioid epidemic. Concurrently, several states now allow the use of medical cannabis to treat a variety of medical conditions, including chronic pain. Needing more exploration is the impact of cannabis laws on general opioid reliance [...]
Lire la suiteThe Effects of Dosage-Controlled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients : Pilot Study Gil Bar-Sela, Daniela Zalman, Valerya Semenysty and Eyal Ballan Integrative Cancer Therapies, 2019, Volume 18, 1–8 DOI: 10.1177/1534735419881498 Abstract Background : Cancer-related cachexia and anorexia syndrome (CACS) is a common phenomenon in cancer patients. Cannabis has been suggested to stimulate appetite but research on this issue has yielded mixed results. The current study aimed to evaluate the effect of dosage-controlled cannabis capsules on CACS in advanced cancer patients. Methods : The cannabis capsules used in this study contained two fractions of oil-based compounds. The planned treatment was [...]
Lire la suiteCannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1–2 Phosphorylation Roger Hudson, Justine Renard, Christopher Norris, Walter J. Rushlow and Steven R. Laviolette Journal of Neuroscience, 2019, 39, (44), 8762-8777 Doi : https://doi.org/10.1523/JNEUROSCI.0708-19.2019 Abstract Evidence suggests that the phytocannabinoids Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) differentially regulate salience attribution and psychiatric risk. The ventral hippocampus (vHipp) relays emotional salience via control of dopamine (DA) neuronal activity states, which are dysregulated in psychosis and schizophrenia. Using in vivo electrophysiology in male Sprague Dawley rats, we demonstrate that intra-vHipp THC strongly increases ventral tegmental area (VTA) DA neuronal frequency [...]
Lire la suitePreclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry Gioacchino Calapai, Carmen Mannucci, Ioanna Chinou, Luigi Cardia, Fabrizio Calapai, Emanuela Elisa Sorbara, Bernardo Firenzuoli, Valdo Ricca, Gian Franco Gensini and Fabio Firenzuoli Hindawi - Evidence-Based Complementary and Alternative Medicine, 2019, Article ID 2509129, 11 pages https://doi.org/10.1155/2019/2509129 Background : Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD is a nonpsychotomimetic substance, and it is considered one of the most promising candidates for the treatment of psychiatric disorders. Objective. &e aim of this review is to illustrate the state of art about scientific research and the evidence of effectiveness of CBD [...]
Lire la suiteBibliographie : Cannabis et Cannabinoides en Psychiatrie Docteur Christian Sueur, GRECC, novembre 2019. Cannabinoïdes et Anxiété Cannabinoïdes et psychose Cannabinoïdes et dépression Cannabinoides et PTSD : cf la Bibliographie : Cannabinoïdes et PTSD https://www.grecc.org/publications/bibliographies/bibliographie-cannabinoides-et-ptsd-docteur-christian-sueur-grecc-2019/ Cannabinoides et Addictions : cf Bibliographie : Substances psychédéliques et Cannabinoïdes, et traitements des Addictions https://www.grecc.org/publications/bibliographies/bibliographie-substances-psychedeliques-et-cannabinoides-et-traitement-des-addictions-dr-christian-sueur-grecc-octobre-2019/
Lire la suiteNotes from the Field : Acute Poisonings from a Synthetic Cannabinoid Sold as Cannabidiol — Utah, 2017–2018 Roberta Z. Horth, Barbara Crouch, B. Zane Horowitz, Amelia Prebish, Matthew Slawson, Jennifer McNair, Chris Elsholz, Stephen Gilley, Jenny Robertson, Ilene Risk, Mary Hill, Linnea Fletcher, Wei Hou, Dallin Peterson, Karlee Adams, Dagmar Vitek, Allyn Nakashima, Angela Dunn MMWR / May 25, 2018 / Vol. 67 / No. 20 US Department of Health and Human Services/Centers for Disease Control and Prevention On December 8, 2017, the Utah Poison Control Center (UPCC) notified the Utah Department of Health (UDOH) of reports of emergency department visits associated with reported [...]
Lire la suiteLabeling Accuracy of Cannabidiol Extracts Sold Online Marcel O. Bonn-Miller, Mallory J.E. Loflin, Brian F. Thomas, Jahan P. Marcu, Travis Hyke, Ryan Vandrey JAMA, 2017, Nov 7, 318, (17), 1708–1709. doi: 10.1001/jama.2017.11909 This study compares ingredients listed on the labels of cannabidiol products sold online to actual product constituents determined by laboratory analysis. There is growing consumer demand for cannabidiol (CBD), a constituent of the cannabis plant, due to its purported medicinal benefits for myriad health conditions. Viscous plant-derived extracts, suspended in oil, alcohol (tincture), or vaporization liquid, represent most of the retail market for CBD. Discrepancies between federal and state cannabis laws have resulted in [...]
Lire la suiteTrends in Internet Searches for Cannabidiol (CBD) in the United States Eric C. Leas, Alicia L. Nobles, PhD, Theodore L. Caputi, Mark Dredze, DaveyM. Smith, JohnW. Ayers JAMA Network Open, 2019, 2, (10), e1913853. doi: 10.1001/jamanetworkopen.2019.13853 Introduction Cannabidiol (CBD) is widely promoted as a panacea. For example, the cannabis brand MedMen claims CBD treats acne, anxiety, opioid addiction, pain, and menstrual problems.1 However, the US Food and Drug Administration has only approved highly purified CBD (Epidiolex) for treating epilepsy. To our knowledge, there is currently no population-focused surveillance of public interest in CBD. Consequently, many question whether CBD should be prioritized by public health leaders [...]
Lire la suite